24,983 Incyte Corporation $INCY Shares Acquired by Crossmark Global Holdings Inc.

Posted by Francis Steltz on Oct 23rd, 2026

Crossmark Global Holdings Inc. lifted its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 28.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 114,122 shares of the biopharmaceutical company’s stock after acquiring an additional 24,983 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Incyte were worth $13,849,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. BlackRock Inc. bought a new position in Incyte during the 2nd quarter valued at about $2,044,189,000. Wellington Management Group LLP lifted its stake in shares of Incyte by 9.5% during the 2nd quarter. Wellington Management Group LLP now owns 3,575,521 shares of the biopharmaceutical company’s stock worth $405,321,000 after acquiring an additional 309,385 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Incyte by 10.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,975,544 shares of the biopharmaceutical company’s stock valued at $185,873,000 after acquiring an additional 187,354 shares during the period. Legal & General Group Plc purchased a new position in Incyte during the 2nd quarter valued at $182,054,000. Finally, Pacer Advisors Inc. grew its position in Incyte by 2.2% in the 1st quarter. Pacer Advisors Inc. now owns 1,741,061 shares of the biopharmaceutical company’s stock valued at $163,869,000 after acquiring an additional 37,790 shares during the last quarter. 96.97% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Patrick Mayes sold 41,899 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $119.46, for a total transaction of $5,005,254.54. Following the transaction, the executive vice president owned 61,441 shares in the company, valued at approximately $7,339,741.86. This trade represents a 40.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pablo Cagnoni sold 10,801 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $125.56, for a total value of $1,356,173.56. Following the transaction, the insider owned 183,200 shares in the company, valued at approximately $23,002,592. This represents a 5.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 55,342 shares of company stock worth $6,659,208 in the last three months. Corporate insiders own 16.20% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Canaccord Genuity Group began coverage on Incyte in a research report on Thursday, August 20th. They issued a “buy” rating and a $152.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $152.00 target price on shares of Incyte in a research report on Tuesday, October 13th. Piper Sandler boosted their target price on shares of Incyte from $110.00 to $130.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. Wall Street Zen cut shares of Incyte from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Finally, JPMorgan Chase & Co. raised their price target on shares of Incyte from $120.00 to $123.00 and gave the stock a “neutral” rating in a research note on Monday, September 28th. Twelve research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $129.90.

Get Our Latest Research Report on Incyte

Incyte Stock Up 3.1%

Shares of NASDAQ:INCY opened at $116.93 on Friday. The business’s 50 day moving average is $121.48 and its 200 day moving average is $111.47. The stock has a market cap of $23.70 billion, a P/E ratio of 14.29, a price-to-earnings-growth ratio of 3.90 and a beta of 0.74. Incyte Corporation has a 52-week low of $84.02 and a 52-week high of $132.60.

Incyte (NASDAQ:INCY – Get Free Report) last issued its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share for the quarter, beating analysts’ consensus estimates of $2.15 by $0.94. Incyte had a return on equity of 29.93% and a net margin of 27.71%. The business had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same period in the previous year, the company posted $1.57 EPS. Incyte’s revenue was up 37.7% on a year-over-year basis. On average, sell-side analysts anticipate that Incyte Corporation will post 2.36 EPS for the current fiscal year.

Incyte Company Profile

(Free Report)

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.